<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004507</url>
  </required_header>
  <id_info>
    <org_study_id>NYX-SNV</org_study_id>
    <nct_id>NCT04004507</nct_id>
  </id_info>
  <brief_title>Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances</brief_title>
  <acronym>SNV</acronym>
  <official_title>Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocuphire Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ophthalmic Consultants of Long Island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ocuphire Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        -  To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the&#xD;
           four endpoints:&#xD;
&#xD;
             1. Contrast sensitivity&#xD;
&#xD;
             2. Low contrast visual acuity&#xD;
&#xD;
             3. Wavefront aberrometry&#xD;
&#xD;
             4. Subjective questionnaire&#xD;
&#xD;
        -  To assess the safety of ophthalmic phentolamine mesylate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-masked, placebo-controlled, single-dose Phase 2 study in 24 patients experiencing&#xD;
      severe night vision difficulties to evaluate ocular and systemic safety and efficacy&#xD;
      following administration of one drop of phentolamine mesylate 1.0% QD in each eye for 1 day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>1 day</time_frame>
    <description>Average change in monocular contrast sensitivity scores under mesopic conditions at each of five spatial frequencies with and without glare</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 day</time_frame>
    <description>Average number of letters of improvement in the following parameters:&#xD;
Distance high-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters)&#xD;
Distance high-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)&#xD;
Distance low-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters)&#xD;
Distance low-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wavefront Aberrometry</measure>
    <time_frame>1 day</time_frame>
    <description>Wavefront aberrometry under mesopic conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Vision Quality</measure>
    <time_frame>1 day</time_frame>
    <description>Subjective patient evaluations of vision quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil Diameter</measure>
    <time_frame>1 day</time_frame>
    <description>Average change in pupil diameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Decrease in Night Vision</condition>
  <condition>Disturbance; Vision, Loss</condition>
  <arm_group>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye (QD) for one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop in each eye (QD) for one day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Mesylate Ophthalmic Solution 1%</intervention_name>
    <description>Topical Sterile Ophthalmic Solution</description>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)</intervention_name>
    <description>Topical Sterile Ophthalmic Solution</description>
    <arm_group_label>Phentolamine Mesylate Ophthalmic Solution Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients â‰¥ 18 years of age&#xD;
&#xD;
          2. Currently experiencing severe night vision difficulty as reported subjectively&#xD;
&#xD;
          3. At least two patches below the normal range at any two frequencies in Contrast&#xD;
             Sensitivity done under mesopic conditions with glare&#xD;
&#xD;
          4. Improvement in low contrast visual acuity (LCVA) in dim light during illumination of&#xD;
             contralateral eye&#xD;
&#xD;
          5. Good general health&#xD;
&#xD;
          6. Written informed consent to participate in this trial&#xD;
&#xD;
          7. Ability to comply with all protocol mandated procedures and to attend all scheduled&#xD;
             office visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with untreated cataracts grades 1-4&#xD;
&#xD;
          2. Patients who wear contact lenses&#xD;
&#xD;
          3. Less than 5 weeks post-refractive surgery (LASIK or PRK)&#xD;
&#xD;
          4. Less than 5 weeks post intraocular lens insertion&#xD;
&#xD;
          5. Low blood pressure (systolic &lt;120 mm Hg or diastolic &lt;80 mm Hg)&#xD;
&#xD;
          6. A history of heart rate abnormalities&#xD;
&#xD;
          7. Administration of any investigational drug within 30 days of study initiation&#xD;
&#xD;
          8. Use of any eye drops with a pharmacologic effect on the pupil within 7 days of Visit 1&#xD;
&#xD;
          9. Use of any systemic alpha adrenergic antagonists (Appendix 1)&#xD;
&#xD;
         10. Known local or systemic hypersensitivity to adrenergic antagonists&#xD;
&#xD;
         11. For women of childbearing potential: currently pregnant or lactating, or unwilling to&#xD;
             use birth control during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marguerite McDonald, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Long Island, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island, NY</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Night Vision Disturbances</keyword>
  <keyword>NVD</keyword>
  <keyword>Glare</keyword>
  <keyword>Halos</keyword>
  <keyword>Starbursts</keyword>
  <keyword>Nyxol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

